A5035989251- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Childhood Cancer Survivors' Quality of Life
- Multiple Myeloma Research and Treatments
- COVID-19 and healthcare impacts
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- COVID-19 Clinical Research Studies
- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Neutropenia and Cancer Infections
- T-cell and B-cell Immunology
- Diabetes and associated disorders
- Immune Cell Function and Interaction
- Vascular Tumors and Angiosarcomas
- Hemoglobinopathies and Related Disorders
- Hematopoietic Stem Cell Transplantation
- Cancer-related gene regulation
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Research Studies
- Memory, violence, and history
Hospital Universitari de Girona Doctor Josep Trueta
2016-2025
Institut Català d'Oncologia
2011-2025
Institut d'Investigació Biomèdica de Girona
2020-2023
Universitat de Girona
2020-2023
Ito Hospital
2022
Trinity College Dublin
1977
Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.This was a Spanish transplant group cell therapy (GETH) multicenter retrospective observational study, which included large cohort blood cancer laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020.We 367 pediatric adult malignancies, including recipients autologous (ASCT) (n = 58) or allogeneic stem transplantation (allo-SCT) 65) 41...
Abstract The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental to assess prognosis postremission therapy patients. However, they been retrospectively validated in few studies with patients included different treatment protocols. We analyzed 861 Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation allocated...
Summary In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) NPM1 mutations (ELNfav AML), although a proportion of these will relapse. Given prognostic importance measurable residual disease (MRD), CETLAM‐12 considered pre‐emptive intervention molecular failure (MF). We analyzed 110 ELNfav AML achieving (CR) after induction chemotherapy....
Abstract Background Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates HMA low there an unmet need finding prognostic predictive biomarkers overall survival. We performed global methylation analysis 75 with MDS secondary AML were included CETLAM...
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type abnormalities, would allow identification high-risk T-ALL patients. Complex karyotype defined by presence ≥3 alterations identified patients with poor prognosis this study. Karyotypes abnormalities accounted for 16 % (22/139) all evaluable karyotypes, corresponding to...
Abstract The negative prognostic impact of internal tandem duplication FLT3 (FLT3-ITD) in patients with acute myeloid leukemia mutated NPM1 (AML-NPM1) is restricted to those a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible wild-type (FLT3WT)/low ITD (FLT3low). Because the comutation DNMT3A (DNMT3Amut) has been suggested negatively influence prognosis AML-NPM1, we analyzed DNMT3Amut subsets (absent, low, high ratios). A total 164 diagnosed AML-NPM1 included 2...
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 adults ≤70 years intensively treated between 2012 2022 CETLAM group. Young ( ≤ 60 years) presented higher remission rates improved survival than older above that age (CR 79% vs. 73%; p = 0.03 4-yr OS 53% 33%; < 0.001). Remission outcomes varied among...
Abstract Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations ( mut). We analyzed impact midostaurin in 227 mut-AML patients included AML-12 prospective trial fit ≤70 years (#NCT04687098). Patients were divided into an early (2012–2015) and late (2016–2020) cohorts. They uniformly treated except addition 71% group patients. No differences observed response rates or number allotransplants between groups. Outcome was improved...
Abstract Relapse is the main cause of treatment failure in T‐cell acute lymphoblastic leukemia (T‐ALL). Despite this, data from adult T‐ALL patients treated with specific chemotherapeutic regimens that examine predictive markers and describe relapse mechanisms are scarce. In this study, we studied 74 paired diagnosis‐relapse samples 37 homogeneously three consecutive measurable residual disease‐oriented trials to identify genetic determinants involved T‐ALL. Analysis single‐nucleotide...
// Laura Palomo 1, 2 , Olga Garcia 3 Montse Arnan 4 Blanca Xicoy Francisco Fuster 1 Marta Cabezón Rosa Coll 5 Vera Ademà Javier Grau Maria-José Jiménez Helena Pomares Sílvia Marcé Mar Mallo Fuensanta Millá Esther Alonso Anna Sureda David Gallardo Evarist Feliu Josep-Maria Ribera Francesc Solé Lurdes Zamora MDS Research Group, Josep Carreras Leukaemia Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de...
Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other neoplasms.The aim of this study was to evaluate the outcome cohort 61 patients with newly diagnosed AML inv(3)/t(3;3) treated homogeneous intensive chemotherapy protocols conducted by Spanish PETHEMA CETLAM cooperative groups between 1999 2017.In retrospective main clinical biologic parameters were collected. The complete response (CR) rate, cumulative...
SARS-CoV-2 infection has bimodal distribution in Europe with a first wave March to June 2020 and second September February 2021. We compared the frequency, clinical characteristics outcomes of adults acute lymphoblastic leukemia (ALL) vs. pandemic waves Spain.In this prospective study ALL COVID-19 infection, comorbidities, treatment outcome two periods were compared. The ended when vaccination against was implemented Spain.Twenty eight patients collected 24 second. median age 46.5 years...
Telangiectasia-associated hepatic fibrosis (TAHF) in a 68-year-old woman with hereditary haemorrhagic telangiectasia (HHT) is described. The patient died of oat-cell carcinoma the lung. In addition to structural alterations which have been described previously HHT, liver exhibited focal midlobular hepatocytic necrosis and tumour metastases. possibility that treatment HHT was causally related some abnormalities found our differentiation TAHF from true cirrhosis are discussed.
Abstract The screening of the BCR::ABL1 kinase domain (KD) mutation has become a routine analysis in case warning/failure for chronic myeloid leukemia (CML) and B-cell precursor acute lymphoblastic (ALL) Philadelphia (Ph)-positive patients. In this study, we present novel DNA-based next-generation sequencing (NGS) methodology KD ABL1 detection monitoring with 1.0E−4 sensitivity. This approach was validated well-stablished RNA-based nested NGS method. correlation both techniques...
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder with heterogeneous clinical, morphological and genetic characteristics. Clonal cytogenetic abnormalities are found in 20-30% of patients CMML. Patients low risk features (normal karyotype isolated loss Y chromosome) account for ∼80% CMML often fall into the categories prognostic scores. We hypothesized that single nucleotide polymorphism arrays (SNP-A) karyotyping could detect cryptic chromosomal alterations impact...
CTLA-4 (cytotoxic T-lymphocyte antigen-4) plays a pivotal role in inhibiting T cell activation through competitive interaction with B7 molecules and interruption of costimulatory signals mediated by CD28. Polymorphisms on the gene have been previously associated autoimmune diseases, predisposition to leukemic relapse, graft-versus-host disease (GVHD) or relapse after allogeneic transplant. As is expressed T-lymphocytes, aim this study was determine whether donor CT60 genotype also influences...
Abstract Background Pediatric‐based or ‐inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome‐negative (Ph‐neg) acute lymphoblastic leukemia (ALL). Methods This study reports results treatment ALLRE08 trial, a full pediatric trial for AYA aged 15‐30 years standard‐risk (SR) ALL. Results From 2008 to 2018, 89 patients (38 [15‐18 years] 51 [YA, 19‐30 years], median age: 20 [15‐29] years) were enrolled in trial. The complete response (CR)...
Abstract BCR-ABL1 -like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent adult ALL using a novel RNA-Seq signature series patients with BCP-ALL. To this end, we developed tested an custom panel 42 genes related cohort 100 BCP-ALL treated risk-adapted trials. Mutations were studied 33 by next-generation sequencing (NGS). Also, CRLF2 overexpression IKZF1 / CDKN2A/B deletions analyzed....
Chromosomal abnormalities are detected in 20–30% of patients with chronic myelomonocytic leukemia (CMML) and correlate prognosis. On the mutation level, disruptive alterations particularly frequent chromatin regulatory genes. However, little is known about consequential epigenetic marking genome. Here, we report analysis genomic DNA methylation patterns 64 CMML 10 healthy controls, using a microarray focused on promoter regions. Differential between controls allowed us to identify...
Abstract Despite high complete remission (CR) rates with frontline therapy, relapses are frequent in adults T‐cell acute lymphoblastic leukemia (T‐ALL) limited salvage options. We analyzed the outcomes and prognostic factors for CR to therapy overall survival (OS) of patients R/R T‐ALL included two prospective measurable residual disease‐oriented trials. Seventy‐five (70 relapsed, 5 refractory) were identified. Relapses occurred bone marrow, isolated or combined 50 patients, central nervous...